New diagnostic technology showcased during Osteoporosis Awareness Month

TAMPA, Florida, May 14, 2021 / PRNewswire / – Medical echolight, present REMS diagnostic technology at Florida Orthopedic Society Annual Scientific Meeting in Tampa, Florida, May 14-15, 2021.

Widely used everywhere Europe (and now becoming available in many countries around the world), REMS is the first without radiation technology provided using a portable Bone densitometer which can safely monitor key indicators of bone health with higher frequency than other testing methods. In a few minutes, REMS provides a patient’s bone health scores and an assessment of their future fracture risk.

A superb 54 million Americans are impacted by osteoporosis and low bone density.

The sooner changes in bone density are identified, the sooner health and fitness professionals can influence patients and clients to make lifestyle changes to build bone mass and prevent further bone loss.

“The way we screen and diagnose patients with osteoporosis is finally changing for the better,” said Douglas tefft, President of Echolight Medical North America. “The portability and ease of use of REMS technology means that screening can begin earlier, which helps to better position patients and their healthcare providers to take meaningful action to prevent the onset of the disease. osteoporosis rather than treating the disease once fractures start to impact quality of life. “

More than half of Americans 50 and older are at high risk of bone fracture, which osteoporosis and osteopenia an urgent public health problem. It is especially important in women, as pregnancy and menopause can lead to loss of bone density. More women die each year from the effects of osteoporosis than from breast and cervical cancer combined.

Chronic health conditions such as diabetes, rheumatoid arthritis, kidney or liver disease, cancer, HIV, and lupus, along with medications to treat these and other conditions, also lead to an increased risk of fracture.

REMS is the first clinically available direct, non-ionizing method of measuring BMD at axial sites, which include the femur and lumbar spine. Its portability has the advantage of detecting and monitoring the bone health of patients at the point of care, creating more possibilities for the early diagnosis and prevention of osteoporosis-related fractures.

Women from 30 with known risk factors are encouraged to speak with their health care provider to discuss bone density screening to establish a baseline before menopause.

Patients who wish to schedule a REMS analysis of talking with their health care provider.

About REMS: Ultrasound radiofrequency multispectrometry (REMS) measures bone density; and reports a T score, Z score and qualitative assessment of bone microarchitecture (independent of bone density) to predict future fracture risk – all delivered within minutes. Portable, diagnostic and radiation-free bone health densitometer – a safe, accurate and cost-effective medical device that elevates bone health awareness and treatment to traditional medical care. Learn more about EcholightMedical.com.

Contact: Jesse landis
[email protected]
813-846-3167

SOURCE Echolight Medical

Related links

https://www.echolightmedical.com/


Source link

Seniors facilities help develop brain health diagnostic technology

SOUTH BURLINGTON, Vt. (WCAX) – New technology uses virtual reality to help early diagnose brain diseases like Alzheimer’s disease, Parkinson’s disease and ALS. The developers of REACT Neuro have tapped dozens of senior residences, including three in Vermont, to help refine the new technique.

Once a week, Betsy Berry meets with staff at The Residence at Quarry Hill in South Burlington and dons a virtual reality headset for a series of five-minute tests. “This is the one where they’re going to give you a written word that’s a color – like the word orange – but they want you to say the word in the color it’s written in,” Berry explained.

These brain games engage his mind and nervous system while measuring his eye movements, vocal responses, and paint a picture of how his brain is functioning. When she first heard that Quarry Hill was offering REACT technology, the former teacher said she wanted to enroll. “I was mesmerized, absolutely mesmerized by the idea that some sort of project was going to come true,” Berry said.

Reporter Cat Viglienzoni: Was this what you thought it was going to be?

Betsy Berry: No it wasn’t … They pissed me off

Reporter Cat Viglienzoni: Because they were difficult?

Betsy Berry: Yeah, and I wanted to show off.

At 80, she says anyone aging is concerned about their brain health, but the reasons for joining were general.

Reporter Cat Viglienzoni: And the hope is then that the information you provide will help someone else down the road?

Betsy Berry: Precisely, yes. This is probably the main reason I wanted to do this.

This is also why Harry Orth, 90, also volunteered. The former University of Vermont English professor says he finds the tests interesting and doesn’t mind being a guinea pig. “It’s part of helping others. I was a teacher – it’s a helping profession – so that’s the kind of thing I’m happy to be a part of, ”he said.

Reporter Cat Viglienzoni: Is this again for you an extension of teaching?

Harry Orth: Yeah, except I don’t have any students. Students will be in the future in another form.

Orth says he hopes this machine will also tell him if his brain is slipping. And that’s precisely why Quarry Hill and their two other Vermont senior residences in Shelburne and Middlebury invested staff time and resources in running these weekly tests for interested residents last fall. “Giving the opportunity to provide residents with insight into their own brain health was something that we thought was a game-changer, honestly, in the industry,” said Ted Doyle, vice president of LCB Senior Living .

He said they were approached by the creators of the REACT Neuro program a few years ago and that with some big names in neuroscience behind the technology, he thinks the science is solid. He says what they learn could allow them to let their residents know if they notice any changes. “It allows us to give them suggestions from a lifestyle perspective on how they can improve their diet, their physical activity, their brain games. Things like that that will have a direct impact on them and help them maintain their brain health, ”Doyle said.

But REACT is not yet approved by the FDA as a diagnostic tool. This is where Doyle says they help. Because, as participants like Berry, Orth and others regularly use this device, they help build a large collection of data that researchers could potentially use to spot patterns and treat brain conditions like Alzheimer’s disease. and Parkinson’s disease. “Ultimately, the promise is that they will be able to give us advice on brain health from day one of our lives,” Doyle said.

“For the first time, we may have the equivalent of a blood pressure cuff for the brain,” said Dr. Rudy Tanzi, co-founder of REACT Neuro, the Massachusetts company behind the technology. He says they are testing this technology on several age groups, not just the elderly. This will allow them to collect data on a wider age range and create a baseline.

They will be going to the FDA at the end of the month to get approval to use for general wellness, similar to a Fitbit or other device. But approval for use in diagnosing brain diseases like Alzheimer’s or Parkinson’s is probably years away.

Copyright 2021 WCAX. All rights reserved.


Source link

NHSX fund diagnostic technology for nursing home residents

The NHSX funded and supported an innovative diagnostic technology solution, allowing GPs to remotely perform a clinical examination during a video call. Residents of 46 care homes in South East London will be the first to gain access to the latest technology.

It is part of the National Innovation Collaborative, which will transform the way residents of Bromley and Lambeth nursing homes access their GPs.

Tara Donnelly, Chief Digital Officer, NHSX, said: “Through the pandemic at NHSX, we have helped test new technology that allows clinicians to monitor and assess the condition of patients remotely.

“As part of our Innovation Collaborative, NHSX is excited to partner with innovators and teams that are transforming care for thousands of people.

“Patients in South East London will now benefit from remote monitoring that goes even further, allowing doctors to monitor their chest and heart problems faster and easier at home.”

Since Covid-19, care homes across the country have adopted “virtual tours of duty,” making video consultations an essential tool for clinicians. This will allow residents to receive high quality care in a timely manner.


Source link

Shields MRI Framingham honored as Center of Excellence in Diagnostics by American College of Radiology – Framingham SOURCE

FRAMINGHAM – Shields Health Care Group announced today that its MRI facility in Framingham has been recognized as a Center of Excellence in Diagnostic Imaging® (DICOE) by the American College of Radiology (ACR).

It is the first Shields MRI center to achieve this prestigious designation and one of the few outpatient diagnostic imaging centers in New England to achieve this prestigious designation.

The DICOE program, which represents the pinnacle of medical imaging care, is an achievement that goes beyond accreditation to recognize best practices in imaging and diagnostic care. This includes a comprehensive assessment of the entire medical imaging business, including structure and results.

The Center of Excellence in Diagnostic Imaging® (DICOE) designation recognizes excellence at many levels, including professional staff, technology and the policies and procedures followed by the organization, as well as superior patient care.

In order to receive this elite distinction, establishments must be accredited by the ACR in all the modalities they offer and in which the ACR offers an accreditation program. Another requirement is participation in the Dose Index Registry® and General Radiology Improvement Database, as well as Image Wisely® and Image Gently®. Shields MRI Framingham underwent a full inspection by a national team, citing the shields as “truly deserving of this seal” early in the process.

As a DICOE facility, Shields MRI Framingham:

  • Provides patients with the utmost confidence to receive today’s highest levels of imaging quality, safety and care;
  • Offers excellence at many levels – professional staff, technology, policies and procedures;
  • Obtained accreditation from the American College of Radiology in all imaging modalities we offer;
  • Has exceeded standard accreditation requirements for the American College of Radiology Center of Excellence in Diagnostic Imaging designation;
  • Has an ongoing self-assessment (and improvement) process, including participation in the ACR Dose Index® registry and general radiology improvement database.

“Shields takes great pride in providing the highest quality diagnostic services while fostering a positive patient experience. This distinction from the ACR is therefore a goal that we are delighted to achieve, ”said Peter Ferrari, President of Shields Health Care Group. “Our Framingham team, Shields clinical advisors and our Quality and Safety Committee which led this initiative, have devoted months of hard work to providing care to our patients, demonstrating our commitment to quality. We look forward to continuing this honor throughout our network over the next several years. “

Shields MRI Framingham is located at 14 Cochituate Road in Framingham.

***

In full transparency, the press release and photos have been submitted to SOURCE media for publication.


Source link

IIT Kharagpur Launches COVIRAP Diagnostic Technology | Latest India News

IIT Kharagpur has successfully marketed its flagship healthcare product COVIRAP, the new zero-diagnostic technology for infectious diseases, including Covid-19, the institute said on Wednesday.

The product, developed by Principal Investigators Professor Suman Chakraborty, Dr Arindam Mondal and their research group, has been licensed for the Rapid Diagnostic Group of Companies, India and Bramerton Holdings LLC, USA.

A virtual press meeting was organized on Wednesday by the institute in which the researchers were present as well as the director of the institute to make the announcement.

“The above decision came at a critical time when the recent surge of Covid-19 infection, commonly known as the second wave, threatened to spread faster than ever before,” said the director of IIT Kharagpur, Professor VK Tewari.

“Additionally, the commercialization of COVIRAP will initiate full indigenization and availability of a wide range of affordable health products in the Indian market as well as the deep trenches of a large global market that literally needs such technology. Tewari said.

Bramerton Holdings has signed a record-breaking deal to secure the worldwide rights to commercialize COVIRAP technology developed at IIT Kharagpur in various geographies outside of the Indian subcontinent, a spokesperson for the institute said.

Rapid Diagnostic has also initiated the adaptation of the COVIRAP technology platform for Covid-19 and tuberculosis, in collaboration with IIT Kharagpur, the spokesperson said.

The research team has now developed a more advanced version of COVIRAP using isothermal step-by-step nucleic acid testing technology for the rapid diagnosis of pathogenic infections, including SARS-CoV-2 in individuals, Chakraborty said. .

The Covid-19 diagnostic test can be performed directly from human swab samples in the portable device developed by the team, without requiring a separate facility for RNA extraction.

Results may be available within 45 minutes of obtaining the sample from the patient, he said.

The kit has also been supplemented with a free smartphone app to facilitate unambiguous interpretation of results and automated delivery to patients.

For the use of the test, nasal samples as well as oral swabs are diluted in a solution and tested in the portable device by mixing them with reagents provided in a pre-mixed form, Chakraborty said, adding that the test s ‘automatically executed in the device without intermediate manual intervention.

“We conducted field trials to run the tests with the help of unqualified personnel outside of a controlled laboratory environment, without compromising the quality of the test result. The entire sample-result procedure can be performed in the handheld device, virtually anywhere and with minimal training, making the testing process more efficient for community-level screening and early detection of any outbreak. emerging infection.

“This can serve as a key to stop the spread of infection at the community level,” Chakraborty hopes.

COVIRAP promises its reach at the local level by meeting the needs of the last person in society, he added.

The researchers claimed that the COVIRAP test overcomes several potential bottlenecks encountered by other similar tests in the past, for example, poor performance outside a highly controlled laboratory and the lack of simple, affordable instruments, but generic and universal that can be used for home and community testing. healthcare for a wide variety of infectious and non-infectious diseases.

Recognizing the impact of COVIRAP technology in meeting longstanding demands for high quality testing at the community level, IIT Kharagpur further initiated the process of deploying this product for use on campus to detect possible new coronavirus infection, the institute spokesperson said. .

Patents centered around this innovation have been filed in India, in the USA, in several other countries, in the name of IIT Kharagpur.

The foreign deposit license was granted recently.

Marketing and use in the United States and Europe under the Emergency Use Authorization (EUA) process is currently underway.


Source link

Coronavirus | IIT Kharagpur launches COVIRAP diagnostic technology

Results may be available within 45 minutes of obtaining the patient sample.

IIT Kharagpur has successfully commercialized its flagship healthcare product COVIRAP, the new zero-diagnostic technology for infectious diseases, including COVID-19, the institute said on Wednesday.

The product, developed by Principal Investigators Professor Suman Chakraborty, Dr Arindam Mondal and their research group, has been licensed for the Rapid Diagnostic Group of Companies, India and Bramerton Holdings LLC, USA.

A virtual press meeting was organized on Wednesday by the institute in which the researchers were present as well as the director of the institute to make the announcement.

“The above decision came at a critical time when the recent surge of COVID-19 infection, commonly known as the second wave, threatened to spread faster than ever before,” said the director of IIT Kharagpur, Professor VK Tewari.

“Further, the commercialization of COVIRAP will initiate full indigenization and the availability of a wide range of affordable health products in the Indian market as well as the deep trenches of a large global market that is literally starved for the need for such technology, ”Mr. Tewari mentioned.

Bramerton Holdings has signed a record-breaking deal to secure the worldwide rights to commercialize COVIRAP technology developed at IIT Kharagpur in various geographies outside of the Indian subcontinent, a spokesperson for the institute said.

Rapid Diagnostic has also initiated the adaptation of the COVIRAP technology platform for COVID-19 and tuberculosis, in collaboration with IIT Kharagpur, the spokesperson said.

The research team has now developed a more advanced version of COVIRAP using isothermal step-by-step nucleic acid testing technology for the rapid diagnosis of pathogenic infections, including SARS-CoV-2 in individuals, said M Chakraborty.

The COVID-19 diagnostic test can be performed directly from human swab samples in the portable device developed by the team, without requiring a separate facility for RNA extraction.

Results in 45 minutes

Results may be available within 45 minutes of obtaining the sample from the patient, he said.

The kit has also been supplemented with a free smartphone app to facilitate unambiguous interpretation of results and automated delivery to patients.

For the use of the test, nasal samples as well as oral swabs are diluted in a solution and tested in the portable device by mixing them with reagents provided in a pre-mixed form, Chakraborty said, adding the tests. . automatically in the device without intermediate manual intervention.

“We conducted field trials to run the tests with the help of unqualified personnel outside of a controlled laboratory environment, without compromising the quality of the test result. The entire sample-result procedure can be performed in the handheld device, virtually anywhere and with minimal training, making the testing process more efficient for community-level screening and early detection of any outbreak. emerging infection.

“This can serve as a key to stop the spread of infection at the community level,” Chakraborty hoped.

COVIRAP promises its reach at the local level by meeting the needs of the last person in society, he added.

The researchers claimed that the COVIRAP test overcomes several potential bottlenecks encountered by other similar tests in the past, for example, poor performance outside a highly controlled laboratory and the lack of simple, affordable instruments, but generic and universal that can be used for home and community testing. healthcare for a wide variety of infectious and non-infectious diseases.

Recognizing the impact of COVIRAP technology in meeting longstanding demands for high quality testing at the community level, IIT Kharagpur further initiated the process of deploying this product for use on campus to detect possible new coronavirus infection, the institute spokesperson said. .

Patents centered around this innovation have been filed in India, in the USA, in several other countries, in the name of IIT Kharagpur.

The foreign deposit license was granted recently.

Marketing and use in the United States and Europe under the Emergency Use Authorization (EUA) process is currently underway.


Source link

Mayo Clinic Launches Joint Ventures to Create and Market AI Diagnostic Tools

James R. Martin / Shutterstock

Mayo Clinic announced wednesday that he has launched two new technology companies designed to harness artificial intelligence (AI) and medical algorithms to create “software as medical devices” that clinicians can use to improve the treatment of different diseases.

The two new companies – Anumana Inc. and Lucem Health Inc. – were launched with a $ 30 million investment from the Mayo Clinic and its venture capital partners.

Anumana completed a $ 25.7 million Series A funding round, led by founding organizations nference and Mayo Clinic and in collaboration with Matrix Capital Management, Matrix Partners and NTVC.

Lucem Health closed a $ 6 million Series A funding round ahead of its launch, led by founders Commure and Mayo Clinic.

In a statement from the Mayo Clinic, the two new tech companies will focus on providing next-generation clinical decision support tools, diagnostic information and care recommendations. Both companies’ AI and medical algorithms will use Mayo Clinic’s medical knowledge, gathered from the organization’s patient records, to develop digital tools that will provide better treatment options for patients with various illnesses.

The companies will leverage Mayo Clinic’s Remote Diagnosis and Management (RDMP) platform, which connects data to innovative new AI algorithms and works to influence clinician decision-making to improve care .

“The dramatically increased use of remote patient telemetry devices, coupled with the rapid acceleration in the development of AI and machine learning algorithms, has the potential to revolutionize diagnostic medicine,” said John Halamka, MD, chair of the Mayo Clinic platform. “With RDMP, clinicians will have access to the best algorithms and care protocols and will be able to serve more patients effectively in remote care environments. The platform will also allow patients to have better control over their health and make better decisions based on the information provided directly to them. “

Anumana will work on the development and commercialization of new digital sensor diagnostic tools using a combination of nference AI and the Mayo Clinic medical data repository. Initially, the new company will focus on developing cutting-edge neural network algorithms, incorporating billions of heart health data from Mayo Clinic’s clinical data analysis platform. This work aims to uncover new biomedical knowledge regarding cardiovascular problems, thus facilitating early detection and better treatments for heart disease.

“For many conditions, such as a weak or thickened heart pump, or silent arrhythmias, there are effective, evidence-based treatments that can prevent heart failure, stroke or death,” Paul said. Friedman, MD, chairman of the Mayo Clinic Department of Cardiovascular Medicine. “The key is to detect the disease before symptoms develop to prevent these events from occurring. The addition of AI to the ECG, a ubiquitous and inexpensive point-of-care test that is already integrated in medical workflows, makes this approach good for patients, convenient for clinicians and extremely scalable. “

The co-founder and CEO of nference and CEO of Anumana, Murali Aravamudan, added, “Our augmented intelligence technology, in the hands of scientific and clinical experts, will enable a complete translation of the language of the heart. We regard it as the Rosetta Stone for cardiac medicine. “

Lucem Health was launched by the Commure and Mayo Clinic to provide the platform that will connect remote patient telemetry devices with algorithms enhanced by AI technology. Ultimately, the company plans to integrate all of the diagnostic information generated from these algorithms into real-world clinical workflows.

“Lucem Health exists to help innovations in diagnostic medicine come to life,” said Sean Cassidy, founding CEO of Lucem Health. “We are excited to be working with partners like the Mayo Clinic and Anumana who are reinventing the way we detect and treat disease. “


Source link

Development of targeted Covid-19 diagnostic tools in a new partnership

The La Jolla Institute of Immunology (LJI), a research organization dedicated to the study of the immune system, has signed a licensing agreement with Leinco Technologies, developer and manufacturer of recombinant proteins, antibodies and conjugates.

Leinco also provides bespoke manufacturing services to the diagnostic and biopharmaceutical industries to take advantage of the proprietary Covid-19 antibodies developed at LJI.

Under the terms of the agreement, Leinco will gain exclusive access to certain SARS-CoV-2 antibodies directed against the virus core (N) protein, which forms the inner envelope of the virus. In addition to developing the antibodies for use in diagnostic applications based on antibodies specific for the N protein, Leinco will make these antibodies commercially available as part of its catalog of research tools.

Most first generation Covid-19 vaccines are directed exclusively against the spike (S) protein on the surface of the virus, but the N protein is just as effective in eliciting a strong antibody response. But more importantly, protein N appears to be less prone to the accumulation of mutations than protein S, for which a number of new mutations have been reported during the pandemic.

Since currently distributed vaccines only induce antibodies against the S protein, the presence of antibodies against N allows physicians to distinguish immune responses resulting from a SARS-CoV-2 infection from a vaccine. based on protein S.

Wm. Pat Leinert Sr., President and CEO of Leinco Technologies, said: “The partnership with the La Jolla Institute of Immunology is a wonderful opportunity to screen, develop and scale up the manufacture of SARS-CoV reagents. -2, in particular antibodies targeting the N protein. Thanks to La Jolla’s in-depth knowledge of infectious diseases and Leinco’s new protein expression platform, combined, we are able to provide reagents and High quality diagnostic tools to the masses and other SARS-CoV-2 research and treatment options. “

These antibodies are the result of a molecular discovery pipeline at LJI developed by structural immunologists Kathryn Hastie and Erica Ollmann Saphire. Saphire is a professor at the Center for Infectious Diseases and Vaccines and director of an international consortium to evaluate therapeutic antibodies against SARS-CoV-2 to prevent and treat COVID-19 (covic.lji.org).

Dr Saphire, whose research focuses on the host-pathogen interface at the molecular level to understand how immune defense can overcome and control viruses, said:

“The high-resolution view of the surface of the interaction between the virus and the immune system, where the rubber meets the road, combined with the precision engineering of the molecules involved, allowed us to discover and develop these antibodies.

“Personally, it’s satisfying to know that the antibodies developed with the unique expertise that my team members bring to the table will provide tools that healthcare professionals, diagnostic labs and other researchers urgently need. to track and treat Covid-19. ”

Discovery pipelines against other diseases are underway.


Source link

Start-up Gregor Diagnostics Advances New Diagnostic Technology

Joel Wipperfurth, Senior Research Associate, performs analysis on Gregor Diagnostic lab benches within Forward BIOLABS. Photo courtesy of the MGE Foundation

From February through June, we’ll spotlight the ways UW-Madison is fueling the state’s economy through research and innovation, educating the next generation, and reaching out to the people of Wisconsin to improve their lives. The theme for February is economic prosperity. Watch for more on #CantStopABadger and #UWimpact on social media. Your support can help us continue this work.

Tobias Zutz found himself looking for a new challenge in 2015.

With R&D experience in test development and molecular diagnostics, he was a member of the R&D team at Exact Sciences that developed Cologuard, a non-invasive colorectal cancer screening test.

So Zutz sat down with Jennifer Gottwald, Director of Licensing at the Wisconsin Alumni Research Foundation, whom he knew from their Masters in Biotechnology program at UW-Madison, to review WARF’s patent portfolio and discuss diagnostic technologies. which could be licensed and potentially marketed.

“One that wasn’t on my list was these methylated DNA biomarkers for prostate cancer, and she put me in touch with David Jarrard, associate director of translational research at the Carbon Cancer Center,” who discovered these biomarkers, ”Zutz explains.

Zutz licensed the technology from WARF and founded Gregor Diagnostics.

“WARF is a key partner,” says Zutz, CEO of Gregor, who also holds a BS in Biochemistry and Genetics from UW-Madison. “He is also an investor.

Gregor Diagnostics is developing a prostate cancer screening test using seminal fluid as a source.

“When I started looking for what to work on next, testing rates had been going down since 2008,” says Zutz. “Prostate cancer is the most diagnosed cancer in men and the second killer, so why are the rates going down? “

Zutz learned about the history and current state of prostate cancer screening and knew there had to be a better solution. With so few people getting reviewed, Zutz saw a huge market opportunity, as did the team at WARF Ventures.

“This is another great opportunity and a much needed solution in the prostate cancer market,” said Greg Keenan, Senior Director – Venture and Accelerator at WARF Ventures. “The market opportunity here is huge. “

“Gregor Diagnostics demonstrates the power of our ecosystem. Gregor is a startup that integrates UW technology and is a prime example of how UW knowledge is translated into companies that solve important problems in the world and create jobs.

Aaron Olver

WARF Ventures invests seed capital in emerging companies and provides connectivity and market expertise, with the goal of advancing technologies in the market and driving a return to UW-Madison. WARF Ventures also attracts venture capital from other regions.

“We’ve been quite successful in leveraging additional VC funds into our businesses through these networks,” says Keenan. “When the talent is in Madison, we bring investor money to those companies.”

Keenan says it’s helpful for Gregor Diagnostics to be part of an ecosystem in Madison that includes big companies like Exact Sciences for potential exit opportunities.

“Toby is a great example of someone who worked at a successful business that developed a cancer diagnosis and then built a business around a technology he found on campus,” Keenan said. “Madison has a long history in diagnostics at UW and with startups. We have a community of diagnostics and business success experts like Exact Sciences. There is a symbiotic relationship between a leading business that benefits the university and UW’s research and technology that can benefit businesses as they grow.

The company uses the basic facilities of UW-Madison, which is both economical and provides access to instrumentation experts from the university.

“We can’t buy an instrument for $ 200,000, but we can rent time on it,” Zutz explains.

The company has published the first results and will begin a second study in March. Next steps will include a large FDA pivotal trial to screen asymptomatic patients, fundraising, and finding a clinical site partner. The company has raised a total of $ 2.9 million to date.

“The ultimate goal is to bring this new screening test to market,” says Zutz.

Gregor Diagnostics is incubating within Forward BIOLABS, an independent nonprofit within the University Research Park that was established to provide lab facilities to start-up biotech startups.

“It was a huge advantage,” Zutz says. “We raised $ 900,000 in 2018 to begin development work, but equipping a full lab costs $ 250,000, so having access to Forward BIOLABS equipment and facilities has really helped. “

In addition, the small team of Gregor Diagnostics benefits from being part of the Forward BIOLABS startup community.

“Having access to a fully equipped lab makes the capital required to start a biotech company more comparable to software startups,” says Aaron Olver, CEO of University Research Park. “The ability of Forward BIOLABS to help businesses at an early and crucial stage and to extend this support well beyond the initial help is crucial. “

Olver says that start-ups frequently “graduate” from Forward BIOLABS to other spaces in the university research park, such as the MG&E Innovation Center.

“Gregor Diagnostics demonstrates the power of our ecosystem,” says Olver. “Gregor is a startup that integrates UW technology and is a great example of how UW knowledge is translated into companies that solve important problems in the world and create jobs. “

“A strong UW-Madison is a key contributor to the birth of new biotechnology companies and jobs,” says Jessica Martin Eckerly, CEO and co-founder of Forward BIOLABS. “Gregor Diagnostics demonstrates how UW-Madison directly affects Wisconsin’s biotech industry – their founder is a UW-Madison graduate who works to bring UW-Madison technology to patients, and he hires UW-Madison graduates to fulfill that mission. Growing the number of UW spin-outs that then hire talented UW graduates and helping those spin-outs succeed is a goal shared by many leaders in our ecosystem.

UW-Madison contributes $ 20.8 billion a year to Wisconsin’s economy, and UW-Madison-related startups contribute an additional $ 10 billion. Read more here.


Source link

NMSU autism diagnostic center open for telehealth appointments

As the pandemic delayed the physical opening of New Mexico State University’s new autism diagnostic center, the center now offers telehealth services to children under 36 months in need of diagnostic evaluation of autism spectrum disorders.

In order to receive treatment, a child must have a medical diagnosis of ASD from a qualified assessment provider. Since the center opened last year, staff have seen strong demand from parents and children, not just from southern New Mexico, but across the state.

While there are several providers of autism assessment, the state’s only other diagnostic center is located at the University of New Mexico, and there is a wait of up to two years for a diagnostic evaluation. Such a long wait could lead to delayed access to necessary interventional services, an increase in the cost of lifelong care and less favorable outcomes.

The evaluations are currently being carried out by Dr Cosette Montañez who leads the interdisciplinary team at ADC. She is a registered psychologist and NMSU Associate Professor in the Department of Communication Disorders. She is also a Stage 1 Applied Behavior Analysis Stage 1 Autism Assessment Practitioner and Board Certified Behavior Analyst.

“We have received referrals from 13 counties, including as far away as Farmington,” Montañez said. “There is such a long wait everywhere, and the pool of diagnostic assessment providers in the state is very limited.”

Montañez has over 15 years of experience performing school and clinical assessments for autism and other neurodevelopmental disorders with children aged 18 months to 17 years. In addition to her degrees and academic training experience, she is bilingual in English and Spanish and is able to work and support people in both languages.

Montañez said the current telehealth process has made it easier for parents to submit documents and conduct interviews online. The CDA will more than likely adopt some of these procedures when the center begins to accept in-person appointments.

A safety plan has been submitted to the NMSU for a return to campus, but no timeline has yet been determined, Montañez said. There are also plans to hire additional staff, including a clinical psychologist, a social worker and an administrative assistant.

The Communication Disorders Department led the project, working closely with former State Senator Mary Kay Papen and NMSU Senior Director of Government Affairs Ricardo Rel to secure funding.

For more information, call the Autism Diagnostic Center at 575-646-3177.

Author: Adriana M. Chavez – NMSU

***

For updates on all the news around Las Cruces and Southern New Mexico, please visit our press partners at Las Cruces Today


Source link